Drug firm Glenmark Pharmaceuticals Thursday reported an 11.07 per cent rise in consolidated net profit to Rs 116.34 crore for the December 2018 quarter, mainly on account of robust sales in India, the US and Europe.
It had posted a net profit of Rs 104.74 crore in the corresponding quarter of the previous fiscal, Glenmark Pharmaceuticals said in a BSE filing.
The company's consolidated revenue stood at Rs 2,555.04 crore during the October-December 2018 period from Rs 2,203.66 crore in the year-ago period.
"We have reported healthy numbers in third quarter on the back of good growth in our key markets like the US, India and Europe," Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha said.
The company continues to receive approval for niche generic products in the US, whereas in India and Europe, it increased market penetration and product launches continue to drive growth, he added.
"We have expanded our presence in the US market through our foray into the branded ..
